Cointime

Tempest Therapeutics

company

About

Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor pathways.

  • 1 - 10

Highlights

Total Funding Amount
$85M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Series B
Last Funding Money Raised
$70M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2011
Number Of Employee
1 - 10
Operating Status
Active

Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response.

Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$85M
Tempest Therapeutics has raised a total of $85M in funding over 2 rounds. Their latest funding was raised on Apr 27, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 27, 2022 Post-IPO Equity $15M 1 — — Detail
Mar 28, 2018 Series B $70M 2 Versant Ventures — Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Tempest Therapeutics is funded by 2 investors. Versant Ventures and Lilly Asia Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Versant Ventures — Post-IPO Equity
Lilly Asia Ventures — Series B
Cointime
เนื้อหา
บริษัท